AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03606642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Synergy® stent
Description: IVUS guided stent
Study NCT02727842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP950 Sound Processor
Description: An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
Study NCT02727842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless programming pod
Description: The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
Study NCT03781427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Description: Left ventricular pacing
Study NCT03781427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy
Description: Left ventricular pacing
Study NCT00645749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Helminth ova
Description: 2500 ova per dose (liquid form)
Study NCT00375037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback
Study NCT00375037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT00375037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT02051231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L
Study NCT01536470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noradrenaline
Description: The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
Study NCT01536470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ephedryne chorydrate
Study NCT02645097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous Nerve Block
Description: A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
Study NCT01050283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: [18F]-FDG PET/CT and Volumetric CT
Description: Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
Study NCT01874600 — intervention group
Intervention type: DEVICE
Intervention: Brain Sentinel Seizure Detection Device and Warning System
Description: The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
Study NCT03730675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal irradiation stent placement
Description: The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
Study NCT03730675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
Study NCT03730675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
Study NCT03730675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
Study NCT02494674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter tracking
Description: Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
Study NCT00741728 — intervention group
Intervention type: OTHER
Intervention: Spider flash EKG, echocardiography tracking, step test
Description: cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
Study NCT01172262 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: This is an observational study, no intervention will occur.
Study NCT02499926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study NCT03881475 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes.
Study NCT03985059 — intervention group
Intervention type: OTHER
Intervention: Transcranial Doppler
Description: Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet.
Study NCT04746898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Students received their basic life support application training through virtual reality glasses with special software.
Study NCT04746898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation Training
Description: Students received their basic life support application training through high fidelity simulator mannequins.
Study NCT04746898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fidelity Simulation Training
Description: Students received their basic life support application training through low fidelity simulator mannequins.
Study NCT06565351 — intervention group
Intervention type: OTHER
Intervention: eGFR estimated from creatinine and cystatin C
Description: eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
Study NCT04053322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
Study NCT04053322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
Study NCT04053322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
Study NCT06322069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention group
Description: Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
Study NCT01210469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening and balance exercises
Description: The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
Study NCT01210469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and balance exercises
Description: The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
Study NCT03000569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Study NCT03000569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
Study NCT03000569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiparkinsonian Agent(s)
Description: Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
Study NCT02705872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h
Description: Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
Study NCT02705872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes
Description: Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
Study NCT03115086 — intervention group
Intervention type: DRUG
Intervention: Cholbam
Description: Cholbam prescribed according to the approved label.
Study NCT02882412 — intervention group
Intervention type: OTHER
Intervention: observational
Study NCT03791138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online patient decision aid
Description: An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: BIS values were arranged 40-60 until the end of operation
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: BIS values were arranged 40-60 until the end of operation
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 microgram/kg infusion, no changes
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: 0.5 mg/kg iv for intubation, no changes
Study NCT02631135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.5 mg/kg iv for intubation, no changes
Study NCT02794948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese medicine granules (HuYang Yang Kun Formula)
Description: Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
Study NCT02794948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dehydroepiandrosterone
Description: The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
Study NCT01025583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hypotonic oral rehydration solution
Description: 30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Study NCT01636024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: Suspension inhaled via Spira nebuliser
Study NCT03360344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio 12 inch Tape
Description: Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
Study NCT03360344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio 4 inch Tape
Description: Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
Study NCT01025583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic oral rehydration solution with Zn and prebiotics
Description: 30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Study NCT04245501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretations (CBM-I)
Description: Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
Study NCT04245501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Description: Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias.
Study NCT02891629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeControl device
Description: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
Study NCT04240730 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal natural orifice endoscopic surgery for endometrial cancer staging
Description: Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
Study NCT02904707 — intervention group
Intervention type: OTHER
Intervention: Questionary EQ-5D
Description: In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
Study NCT00751491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosin
Description: Intracoronary Adenosin 50 microg;
Study NCT00751491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention
Study NCT00751491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 300/600 mg
Study NCT00580073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
Study NCT00580073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
Study NCT01434303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT01434303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01434303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT01434303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT01636024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Matching placebo inhaled via Spira nebuliser
Study NCT02032537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Callmax cream application over affected skin
Description: Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
Study NCT02032537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
Study NCT00649467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose applesauce
Study NCT00649467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsules 25 mg
Description: 25mg, single dose applesauce
Study NCT02931695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of QT interval duration
Description: ECG to evaluation of QT interval duration
Study NCT02931695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: circulating sex hormones levels sample
Description: Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
Study NCT00300469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks
Study NCT00300469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks
Study NCT00300469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information
Study NCT00300469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information
Study NCT00300469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 12 weeks, see Arm Description for placebo information
Study NCT02251054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar group
Description: We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
Study NCT02251054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Avatar group
Description: We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
Study NCT01595035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
Study NCT04257734 — intervention group
Intervention type: OTHER
Intervention: observation
Description: different serum antibodies status
Study NCT03136185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.
Study NCT01233401 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
Study NCT02733614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: novel V1a receptor antagonist
Study NCT02733614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02072317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxel plus raltitrexed
Description: taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
Study NCT02072317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxol
Description: taxol 135 mg/m2, every three weeks for a cycle
Study NCT02949115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 70 mL red beetroot juice
Description: 1x daily intake of 70 mL red beetroot juice